Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells

Experimental Cell Research

Volumn 318, Issue 7, 2012, Pages 819-827

  van Heumen, Bjorn W H ^a   Roelofs, Hennie M J ^a   Te Morsche, René H M ^a   Marian, Brigitte ^b   Nagengast, Fokko M ^a   Peters, Wilbert H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Celecoxib; Familial adenomatous polyposis; HT 29; LT97; Ursodeoxycholic acid

Indexed keywords

CASPASE 3; CELECOXIB; CYCLINE; CYCLOOXYGENASE 2; TAUROCHENODEOXYCHOLIC ACID; TAUROCHOLIC ACID; TAUROURSODEOXYCHOLIC ACID;

ADENOMATOUS POLYP; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; COLON CANCER; COLORECTAL ADENOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84858284107     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.02.004     Document Type: Article

References (40)

1. Bodmer W.F., Bailey C.J., Bodmer J., et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987, 328:614-616.
2. Bulow S. Results of national registration of familial adenomatous polyposis. Gut 2003, 52:742-746.
3. Belchetz L.A., Berk T., Bapat B.V., Cohen Z., Gallinger S. Changing causes of mortality in patients with familial adenomatous polyposis. Dis. Colon Rectum 1996, 39:384-387.
4. de Campos F.G., Perez R.O., Imperiale A.R., et al. Evaluating causes of death in familial adenomatous polyposis. J. Gastrointest. Surg. 2010, 14:1943-1949.
5. Bulow S., Bjork J., Christensen I.J., et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004, 53:381-386.
6. Vasen H.F., Bulow S., Myrhoj T., et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut 1997, 40:716-719.
7. de Vos tot Nederveen Cappel W.H., Järvinen H.J., Björk J., Berk T., Griffioen G., Vasen H.F. Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis. Br. J. Surg. 2003, 90:705-710.
8. Latchford A.R., Neale K.F., Spigelman A.D., Phillips R.K., Clark S.K. Features of duodenal cancer in patients with familial adenomatous polyposis. Clin. Gastroenterol. Hepatol. 2009, 7:659-663.
9. de Castro S.M., van Eijck C.H., Rutten J.P., et al. Pancreas-preserving total duodenectomy versus standard pancreatoduodenectomy for patients with familial adenomatous polyposis and polyps in the duodenum. Br. J. Surg. 2008, 95:1380-1386.
10. Greenhough A., Smartt H.J., Moore A.E., et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
11. Arber N., Eagle C.J., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006, 355:885-895.
12. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006, 355:873-884.
13. Oshima M., Dinchuk J.E., Kargman S.L., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803-809.
14. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342:1946-1952.
15. Debinski H.S., Trojan J., Nugent K.P., Spigelman A.D., Phillips R.K. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 1995, 345:855-856.
16. Phillips R.K., Wallace M.H., Lynch P.M., et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002, 50:857-860.
17. Shekels L.L., Beste J.E., Ho S.B. Tauroursodeoxycholic acid protects in vitro models of human colonic cancer cells from cytotoxic effects of hydrophobic bile acids. J. Lab. Clin. Med. 1996, 127:57-66.
18. Alberts D.S., Martinez M.E., Hess L.M., et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J. Natl. Cancer Inst. 2005, 97:846-853.
19. Tung B.Y., Emond M.J., Haggitt R.C., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann. Intern. Med. 2001, 134:89-95.
20. Pardi D.S., Loftus E.V., Kremers W.K., Keach J., Lindor K.D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.
21. Wali R.K., Khare S., Tretiakova M., et al. Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1653-1662.
22. Khare S., Mustafi R., Cerda S., et al. Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr. Cancer 2008, 60:389-400.
23. Jacoby R.F., Cole C.E., Hawk E.T., Lubet R.A. Ursodeoxycholate/sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 2004, 127:838-844.
24. Richter M., Jurek D., Wrba F., et al. Cells obtained from colorectal micro-adenomas mirror early premalignant growth patterns in vitro. Eur. J. Cancer 2002, 38:1937-1945.
25. Barker G.M., Radley S., Bain I., et al. Biliary bile acid profiles in patients with familial adenomatous polyposis before and after colectomy. Br. J. Surg. 1994, 81:441-444.
26. Berkhout M., Roelofs H.M., Friederich P., et al. Ursodeoxycholic acid intervention in patients with familial adenomatous polyposis: a pilot study. Transl. Res. 2007, 150:147-149.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
28. Lev-Ari S., Strier L., Kazanov D., et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin. Cancer Res. 2005, 11:6738-6744.
29. Grösch S., Tegeder I., Niederberger E., Bräutigam L., Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001, 15:2742-2744.
30. Schiffmann S., Maier T.J., Wobst I., et al. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem. Pharmacol. 2008, 76:179-187.
31. Lev-Ari S., Kazanov D., Liberman E., Ben-Yosef R., Arber N. Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines. Dig. Dis. Sci. 2007, 52:1128-1133.
32. van der Valk J., Brunner D., de Smet K., et al. Optimization of chemically defined cell culture media-replacing fetal bovine serum in mammalian in vitro methods. Toxicol. In Vitro 2010, 24:1053-1063.
33. Battu S., Rigaud M., Beneytout J.L. Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL.19A. Anticancer Res. 1998, 18:3579-3583.
34. Davies N.M., McLachlan A.J., Day R.O., Williams K.M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet. 2000, 38:225-242.
35. Huang F., Hsu S., Yan Z., Winawer S., Friedman E. The capacity for growth stimulation by TGF beta 1 seen only in advanced colon cancers cannot be ascribed to mutations in APC, DCC, p53 or ras. Oncogene 1994, 9:3701-3706.
36. Shao J., Sheng H., Inoue H., Morrow J.D., DuBois R.N. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biol. Chem. 2000, 275:33951-33956.
37. Jurek D., Fleckl E., Marian B. Bile acid induced gene expression in LT97 colonic adenoma cells. Food Chem. Toxicol. 2005, 87-93.
38. Maier T.J., Schilling K., Schmidt R., Geisslinger G., Grösch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 2004, 67:1469-1478.
39. Grösch S., Maier T.J., Schiffmann S., Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 2006, 98:736-747.
40. Patel M.I., Subbaramaiah K., Du B., et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin. Cancer Res. 2005, 11:1999-2007.